

Version 1.0.3

Submission[Home](#) > [Submission](#)

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

| Submission Details | |
|--------------------|---|
| Status | Accepted |
| Open Date | 01/10/2019 |
| Deadline Date | 30/10/2019 |
| Date Submitted | 30/10/2019 |
| Type | Performance In Delivering |
| NHS provider | Maidstone and Tunbridge Wells NHS Trust |

Showing records 1 to 6 of 6.

Pages: 1

| Id | Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial | Comments |
|-------|--|---|--|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|--|
| 42875 | 16/LO/0880 | 205661 | CREDO 2 - A randomised, double blind, parallel-group, placebo and active controlled, multicentre phase III study of the efficacy and safety of Olokizumab in subjects with moderately to severe active Rheumatoid Arthritis inadequately controlled by Metho | Number Agreed | 6 | 6 | Not Available / Not Agreed | | | 13/11/2018 | 1 | Recruitment Finished | Pts screened but not eligible due to not fitting the inclusion criteria. |
| 42876 | 17/SW/0221 | 232448 | Surpass | Number Agreed | 2 | 2 | Date Agreed | 27/06/2019 | 0 | 11/10/2018 | 0 | Withdrawn By Sponsor | Site closed by sponsor due to no pts recruited. This was due to a change in standard practice making eligibility of patients difficult |
| 42877 | 17/LO/0957 | 226146 | A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis. | Number Agreed | 1 | 1 | Date Agreed | 03/08/2019 | 1 | 24/05/2019 | 1 | Recruitment Finished | |
| 42878 | 15/EM/0400 | 178129 | A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment | Number Agreed | 5 | 5 | Not Available / Not Agreed | | 5 | 10/10/2018 | 2 | Recruitment Finished | |
| 42879 | 17/NW/0351 | 224954 | A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma | Number Agreed | 6 | 6 | Not Available / Not Agreed | | 0 | 28/11/2018 | 0 | Recruitment Finished | Pts screened, eligibility criteria difficult to recruit to |
| 42880 | 17/NE/0149 | 224550 | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) | Number Agreed | 3 | 3 | Not Available / Not Agreed | | 1 | 12/07/2019 | 1 | Recruitment Finished | Pts screened but not eligible due to being too ill to be recruited. |

Showing records 1 to 6 of 6.

Pages: 1

10/30/2019

CTP Submission Platform - Submission (Version 1.0.3)

< Back

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by [Exbos Limited](#) the bespoke software specialists.

